Solidifying a new corporate structure, IFM launches second unit focused on cGAS-STING
For Gary Glick and his crew at IFM, life after spinning out their oncology assets to Bristol-Myers Squibb has involved constant discussions about which …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.